Palumbo Wealth Management LLC has made a significant investment by acquiring a stake in Boston Scientific Corporation, purchasing 25,330 shares valued at approximately $2.4 million. This acquisition occurred during the third quarter and was documented in a recent filing with the Securities and Exchange Commission.
The investment landscape for Boston Scientific (NYSE: BSX) has seen various institutional players adjusting their holdings. Notably, First American Trust FSB increased its position by 0.3%, now owning 80,908 shares worth $7.9 million after acquiring an additional 237 shares. Mufg Securities Americas Inc. has also expanded its stake by 21.9%, bringing its total to 39,957 shares valued at $3.9 million following the purchase of 7,168 shares in the last quarter.
Baldwin Investment Management LLC and Compound Planning Inc. have both enhanced their positions, with Baldwin increasing its holdings by 5.4% to 13,145 shares worth $1.3 million, and Compound Planning lifting its stake by 22.1% to 13,445 shares valued at approximately $1.3 million. Currently, institutional investors hold approximately 89.07% of Boston Scientific’s stock.
Stock Performance and Insider Activity
On Tuesday, shares of Boston Scientific opened at $74.37. The company boasts a market capitalization of $110.36 billion, with a price-to-earnings ratio of 38.33. Over the past year, the stock has fluctuated between a low of $72.69 and a high of $109.50. Other financial metrics include a current ratio of 1.62, a quick ratio of 1.08, and a debt-to-equity ratio of 0.46.
Recent insider trading activity has caught the attention of market watchers. Executive Vice President Arthur C. Butcher sold 17,313 shares on December 1, 2023, at an average price of $101.55, totaling approximately $1.76 million. Following this transaction, Butcher holds 23,600 shares valued at around $2.4 million, reflecting a 42.32% decrease in his ownership.
Similarly, CEO Michael F. Mahoney sold 160,901 shares on February 2, 2024, at an average price of $93.49, amounting to about $15 million. After this sale, Mahoney retains 1,411,735 shares, valued at approximately $132 million, which is a 10.23% decrease in his holdings.
Analyst Ratings and Future Outlook
The performance of Boston Scientific has prompted various analysts to reassess their ratings. According to recent reports, Weiss Ratings downgraded the stock from a “buy” to a “hold” rating. Evercore adjusted its target price from $112.00 to $96.00, maintaining an “outperform” rating. Other notable adjustments include Oppenheimer, which reduced its price target from $125.00 to $100.00, and Morgan Stanley lowering its target from $130.00 to $118.00.
Despite these changes, the consensus rating remains a “Moderate Buy” with an average price target of $108.36, supported by one analyst rating it as a Strong Buy, twenty as Buy, and three as Hold.
Boston Scientific Corporation, headquartered in Marlborough, Massachusetts, has established itself as a leader in the global medical device industry. Founded in 1979 by John Abele and Peter Nicholas, the company specializes in developing, manufacturing, and marketing products for less-invasive medical procedures. Its portfolio addresses various medical disciplines including cardiovascular, digestive, urologic, and chronic pain conditions.
As institutional investors continue to play a significant role in Boston Scientific’s stock, the company remains a focal point for market analysts and investors alike, reflecting ongoing interest in the medical devices sector.
